
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
2026-11-18 10:10:30Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 September 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with the latest comprehensive analysis.
Read More
Oxygenta Pharmaceutical Ltd Reports Flat Quarterly Performance Amid Margin Pressures
2026-11-11 11:00:32Oxygenta Pharmaceutical Ltd’s latest quarterly results for September 2026 reveal a marked shift in financial momentum, with the company’s growth trajectory flattening after a period of robust expansion. Despite a strong surge in net sales, rising interest expenses and a deteriorating financial trend score have weighed on investor sentiment, prompting a downgrade to a Strong Sell rating.
Read More
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
2026-10-31 10:10:13Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 31 October 2026, providing investors with the latest comprehensive view of the company’s position.
Read More
Oxygenta Pharmaceutical Ltd Forms Death Cross Signalling Bearish Trend
2026-10-29 18:00:52Oxygenta Pharmaceutical Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a sustained bearish trend, reflecting deteriorating momentum and long-term weakness in the stock’s price action.
Read More
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
2026-09-28 10:10:37Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 September 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 28 September 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreOxygenta Pharmaceutical Gains 3.14%: 2 Key Technical Signals Shape Weekly Momentum
2026-09-12 14:02:31Key Events This Week 7 Sep: Stock opens at Rs.53.83 amid Sensex decline 8 Sep: Golden Cross formation signals potential bullish breakout; stock rises 3.05% 9 Sep: MarketsMOJO upgrades rating to Sell; stock dips 1.97% 11 Sep: Stock rebounds with 3.87% gain closing at Rs.55.88 Week OpenRs.54.18 Week Close<div class="sta...
Read More
Golden Cross Forms in Oxygenta Pharmaceutical Ltd — On a Day the Stock Gained 3.05%. What the Mixed Signals Mean
2026-09-08 18:00:53The 50-day moving average has crossed above the 200-day moving average for Oxygenta Pharmaceutical Ltd on 8 Sep 2026, signalling a golden cross. Yet, the stock’s 3.05% gain on the day contrasts with a mixed technical backdrop, where monthly momentum indicators remain bearish. This divergence invites a closer look at whether the golden cross stands as a reliable signal or a lone beacon amid conflicting data.
Read More
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
2026-08-31 10:10:39Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read MoreUn-Audited Financial Results For The Quarter And Half-Year Ended 30.09.2026.
10-Nov-2026 | Source : BSEUn-audited Financial Results for the Quarter and Half-year ended 30.09.2026.
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday I.E. 10Th November 2026.
10-Nov-2026 | Source : BSEOutcome of Board Meeting held on Tuesday i.e. 10th November 2026.
Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2026.
05-Nov-2026 | Source : BSECorporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available